Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 2, 1998

View Archived Issues

Licensing opportunity from the NIH: technology for enhancing embryo implantation

Licensing opportunity from the NIH: method of protecting neural cells from apoptosis

Aminoacyl sulfamides synthesized at Cubist claimed for psoriasis

New K+ channel blockers for arrhythmias, ulcers and related disorders

Licensing opportunity from NIH: antiretroviral agents with unique mechanism of action

Chiron pinpoints site of HCV binding to host cells

HMR presents new agents for lipid disorders

Oncocidin A1: a novel microtubule-binding antitumor agent

InKine: Annual Report 1998

Selective, nonpeptide Y1 receptor antagonist reduces NPY-mediated food intake in rats

FDA okays U.S. portion of multinational study evaluating Theratope

Hungarian research team presents new antithrombotic thioglycosides

PIXY-321 performs favorably in children; compound unfortunately no longer in development

Prosorba Column recommended for approval by FDA advisory panel

Inhibition of ceramide glucosyltransferase as a novel therapeutic target

Continuing efforts at Parke-Davis result in structurally novel functional ETA receptor antagonist

Ibex Technologies: Q4 and year-end 1998 highlights

Positive CPMP opinion issued for Betaseron in new indication

Positive pivotal trial results for enzyme replacement therapy to be submitted with BLA

Synthelabo: nine-month highlights

Safety and efficacy of COX-2 inhibitor established in phase II trials

Japan Tobacco will acquire Torii in stock-purchase action

Targeted Genetics receives patent coverage for cellular therapy platform

Vivus: Q3 and nine-month highlights

Transkaryotic Therapies: Q3 1998 highlights

Liposomal GPI-2A associated with unexpected side effects in early clinical trial

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...